|Other Names||Melanoma-associated antigen 4, Cancer/testis antigen 14, CT14, MAGE-4 antigen, MAGE-41 antigen, MAGE-X2 antigen, MAGEA4, MAGE4|
|Target/Specificity||The synthetic peptide sequence is selected from aa 24~38 of human MAGEA4.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Not known, though may play a role in embryonal development and tumor transformation or aspects of tumor progression.|
|Tissue Location||Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes and placenta|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
MAGEA4 is a member of the MAGEA gene family. The members of this family have their entire coding sequences located in the last exon, and the encoded proteins show 50 to 80% sequence identity between each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are expressed at a high level in a number of tumors of various histologic types, and are silent in normal tissues with the exception of testis and placenta. The MAGEA genes are clustered on chromosome Xq28. They may be implicated in some hereditary disorders, such as dyskeratosis congenita. Multiple alternatively spliced transcript variants differing in the 5' exon have been found for this gene, however, the full length nature of different variants has not been defined.
Nagao, T., et al., J. Biol. Chem. 278(12):10668-10674 (2003).Resnick, M.B., et al., Int. J. Cancer 101(2):190-195 (2002).Imai, Y., et al., Gene 160(2):287-290 (1995).Rogner, U.C., et al., Genomics 29(3):725-731 (1995).De Plaen, E., et al., Immunogenetics 40(5):360-369 (1994).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.